Results

Most recent

AMD-Neovascular

1–3 of 3 results for DAVIO 2

Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration
Jennifer I. Lim, MD, FARVO, FASRS
Annual Meeting Talks
2025
Treatment Burden in Wet Age-Related Macular Degeneration Treated With EYP-1901 vs Aflibercept in DAVIO 2, a Phase 2 Clinical Trial
Avni P Finn, MD, MBA, FASRS
Annual Meeting Talks
2025
Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2024